Quest Diagnostics Incorporated (NYSE:DGX) has steadily been on the rise with various accomplishments and significant milestones. The company has raised its dividend to $0.80 per share, displaying strong financial health and promising returns for shareholders. Besides, it has been selected in Fortune's World's Most Admired Companies List for an impressive 11th consecutive year, underlining the firm's continuous commitment to innovation and excellence. The company has shown strong trading performance, outperforming competitors on several trading days. Quest Diagnostics recently completed two key acquisitions - University Hospitals' Outreach Lab Services Business and LifeLabs - further consolidating its leadership in diagnostic services. The company's Q4 2024 earnings showcased impressive growth with Q4 revenue hitting a massive $2.62 billion. The firm's financial performance is widely expected to continue its bullish trend in the future as per several analysts' ratings and price target adjustments from financial firms like Baird, Jefferies, Barclays, Truist Securities, and more. The company has further promised more focus on advanced diagnostics and acquisitions targeting a revenue between $10.7B and $10.85B for 2025.
Quest Diagnostics DGX News Analytics from Wed, 01 May 2024 07:00:00 GMT to Sat, 01 Feb 2025 17:26:26 GMT - Rating 7 - Innovation 8 - Information 9 - Rumor -5
